1-3 of 3
Vesna Najfeld
Close
Sort by
Journal Articles

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

Clinical Trials & Observations
John O. Mascarenhas, Raajit K. Rampal, Heidi E. Kosiorek, Rupali Bhave, Elizabeth Hexner, Eunice S. Wang, Aaron Gerds, Camille N. Abboud, Marina Kremyanskaya, Dimitry Berenzon, Olatoyosi Odenike, Noushin Farnoud, Aishwarya Krishnan, Rona Singer Weinberg, Erin McGovern, Mohamed E. Salama, Vesna Najfeld, Juan S. Medina-Martinez, Juan E. Arango Ossa, Max F. Levine, Yangyu Zhou, Lonette Sandy, Mark L. Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5246–5256.
https://doi.org/10.1182/bloodadvances.2020002119
Published: 2020
Includes: Supplemental data
Journal Articles

Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53

Clinical Trials & Observations
Bridget K. Marcellino, Ronald Hoffman, Joseph Tripodi, Min Lu, Heidi Kosiorek, John Mascarenhas, Raajit K. Rampal, Amylou Dueck, Vesna Najfeld
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3581–3589.
https://doi.org/10.1182/bloodadvances.2018024018
Published: 2018
Journal Articles

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

Clinical Trials & Observations
Raajit K. Rampal, John O. Mascarenhas, Heidi E. Kosiorek, Leah Price, Dmitriy Berenzon, Elizabeth Hexner, Camille N. Abboud, Marina Kremyanskaya, Rona Singer Weinberg, Mohamed E. Salama, Kamal Menghrajani, Vesna Najfeld, Lonette Sandy, Mark L. Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Judith D. Goldberg, Ronald Hoffman
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3572–3580.
https://doi.org/10.1182/bloodadvances.2018019661
Published: 2018
Includes: Supplemental data